

# Medicinal Applications and Toxicological Activities of *Aloe* Products

V. Steenkamp<sup>1</sup> and M.J. Stewart<sup>2</sup>

<sup>1</sup>Department of Pharmacology, University of Pretoria, Pretoria, South Africa; <sup>2</sup>Forensic Pathology Services, Department of Health, Pretoria, South Africa

## Abstract

*Aloe* (Liliaceae) has long been used as a remedy in many cultures. *Aloe* products, which include the latex, gel, and whole leaf, are used, among other reasons, as laxatives, in creams for skin ailments, and as a treatment for a wide range of diseases, respectively. The heterogeneous nature of *Aloe* products may contribute to the diverse biological and therapeutic activities that have been observed. Variations in the composition of *Aloe* can result in products with different chemical and physical properties, making the comparison of products difficult. In this article, the chemistry, uses, pharmacological activity, and toxicity of *Aloe* gel, latex, and isolated compounds are reviewed. This article is confined to literature pertaining to *Aloe vera* (L.) Burm.f. (also known as *A. barbadensis* Miller) and *Aloe ferox* Miller since they are the most widely used species both commercially and for their therapeutic properties.

**Keywords:** *Aloe*, *Aloe barbadensis*, *Aloe ferox*, *Aloe* gel, *Aloe* latex, *Aloe vera*.

## Introduction

There are approximately 500 species of the genus *Aloe* (Liliaceae) (Swanson, 1995), of which 160 are indigenous to South Africa. Many of these are used in traditional healing (Lindsey et al., 2002). “Aloes” is the generic name for the solid residue obtained by boiling and cooling the latex of *Aloe ferox* Miller, its hybrids, and *A. vera* (L.) Burm.f. (also known as *A. barbadensis* Miller). *Aloe* has long been used as a remedy in many cultures. There are anecdotal references to its use in ancient Egypt in 1500 B.C., and it is mentioned in the pharmacopoeia produced by Dioscorides in the first century A.D.

(Castleman, 1991). *Aloe* gel, the clear jelly-like substance obtained from the parenchymatous cells in the inner leaf, was first used clinically in the 1930s for the treatment of radiation burns (Tyler et al., 1981). Today, *Aloe* gel is a familiar ingredient used in ointments and the cosmetic industries. The latex, found in the pericyclic cells in the margins of the leaves, is mainly used for its laxative effect. In this paper, the chemistry, uses, pharmacological activity, and toxicity of *Aloe* gel, latex, and isolated compounds are reviewed. This article is confined to literature pertaining to *Aloe vera* and *Aloe ferox* since they are the most widely used species both commercially and for their therapeutic properties.

## Botany of the *Aloe* plant

*Aloe ferox* and *A. vera* belong to the family Liliaceae and the tribe Aloineae. *Aloe* are perennial succulents and are characterized by stemless large, thick, fleshy leaves that are lance shaped and have a sharp apex and a spiny margin. *Aloe* leaves have a yellow latex, which is referred to as *Aloe* juice or sap and has a bitter taste. The leaf pulp is the innermost portion of the leaf and is composed of the parenchyma cells that contain the gel. Although *A. vera* originated in the warm, dry climates of Africa, the plant is readily adaptable and occurs naturally worldwide.

## Chemistry

*Aloe* gel contains polysaccharides, primarily of  $\beta$ -(1,4)-linked, polydispersed, highly acetylated mannans (hence “acemannan”) with an average molecular weight of

Accepted: December 5, 2006.

Address correspondence to: Dr. V. Steenkamp, Dept. of Pharmacology, University of Pretoria, P.O. Box 2034, Pretoria, 0001, South Africa. Tel.: +27-12-319 2547; Fax: +27-12-319 2411; E-mail: vsteen@med.up.ac.za

1000 kDa (Femenia et al., 1999). The polysaccharides are unstable and are affected by acidity, certain enzymes, and heat (Femenia et al., 2003). *A. vera* gel contains three malic acid acylated carbohydrates: Veracylglucans A, B, and C. All three compounds demonstrate anti-inflammatory effects, but whereas Veracylglucan A and Veraglucan B possess anti-proliferative effects, Veraglucan C enhances cell proliferation (Esua & Rauwald, 2006).

The main active constituents of the latex are anthraquinones, which include aloins A and B, barbaloin, isobarbaloin, and emodin (Wichtl & Bisset, 1994). Also included are aloe-emodin, resins, aloesin and its aglycone, aloesone, and chromone derivatives (Wichtl & Bisset, 1994). Other potentially active constituents are lipids, amino acids, enzymes, and sterols (Bruneton, 1995).

*Aloe* contains the enzymes carboxypeptidase and bradykinase, both of which have been shown to relieve pain and decrease inflammation and swelling (Duke, 1997). Salicylic acid has also been detected in *A. vera* (Robson et al., 1982), as has a relatively high concentration of mannose 6-phosphate (Davis et al., 1994). The potent anti-oxidative compound 8-C- $\beta$ -D-glucopyranosyl-2-propyl-7-methoxy-5-methylchromone, has been isolated from a methanol extract of *A. vera* (Lee, 2000) and isoaloesin (2-acetonyl-6-C- $\beta$ -D-glucopyranosyl-7-hydroxy-5-methylchromone) from the leaves of this plant (Yuan, 1993; Yuan et al., 1991). The anti-inflammatory compound aloeresin I was recently isolated from *A. ferox* (Speranza et al., 2005). The presence of two dihydrocoumarins with immunomodulatory and antioxidative properties has also been reported (Zheng et al., 2006).

Studies of the concentrations of the major compounds in fresh *A. ferox* leaf exudates have shown them to be remarkably consistent, with aloeresin A, aloesin, and aloin (both epimers A and B) contributing between 70 and 97% of total dry weight, in a ratio of approximately 4:3:2, respectively (van Wyk et al., 1997). The age of the plant plays a role in the levels of polysaccharides and flavonoids (Hu et al., 2003), as do climatic conditions. The concentrations in the final products depend on the preparation technique used (Reynolds & Dweck, 1999).

## Methods of Detection

### *In body fluids*

Detection of aloin and its metabolites in urine is possible using thin-layer chromatography (Perkins & Livesey, 1993). In plasma, High-performance liquid chromatography (HPLC) is more sensitive, with a limit of detection (LOD) of 4.5 ng/ml (Zaffaroni et al., 2003).

### *In plant material*

Methods reported include micellar electrokinetic chromatography (Kuzuya et al., 2001), Gas chromatography-mass

spectrometry (GC-MS) (Saccu et al., 2001), capillary zone electrophoresis (Wang et al., 2000), HPLC (Cao & Liu 2003), and size exclusion chromatography with refractive index detection (Turner et al., 2004).

### *In pharmaceuticals*

HPLC has been used to quantitate barbaloin in *Aloe* capsules, with an LOD of 0.002  $\mu$ g (Chen et al., 2002) and for the detection of *Aloe* components in creams (Yamamoto et al., 1985). A quantitative colorimetric assay for glucomannan in *Aloe* products was described by Eberendu et al. (2005); this method showed negligible interference by non-*Aloe* polysaccharides and was rapid, producing results within 5 min. GC-MS with a LOD of 0.005 ppm for aloe-emodin and 0.05 ppm for aloin (ElSohly et al., 2004) and size exclusion chromatography with refractive index detection (Turner et al., 2004) may also be used. GC-MS has been employed to detect *Aloe* components in cosmetic products (Nakamura & Okuyama, 1990).

### *Food*

An HPLC method (Yamamoto et al., 1985) and an interesting rapid amplified polymorphic DNA method (Shioda et al., 2003) have been applied to detect *Aloe* compounds in food.

### *Herbal remedies*

Micellar electrokinetic chromatography with an LOD of 10  $\mu$ g/ml has been applied to Chinese teas (Zheng et al., 2004). Capillary zone electrophoresis has also been used to detect *Aloe* components in Chinese medicine (Wang et al., 2004). HPLC was employed to detect the presence of aloesin and aloeresin A in an African traditional remedy (Wang et al., 2003).

## Uses

### Medicinal

Although the use of *Aloe* was recorded by the Egyptians, Assyrians, and Mediterranean peoples as far back as 1500 B.C., the Greek physician Dioscorides was the first to describe the use of *Aloe* to treat mouth infections, sores, and wounds and as a purgative. *Aloe* has been used in India as a cathartic, stomachic, emmenagogue, and anthelmintic and more recently in England and in the USA and Mexico for the treatment of diseases of the immune system (Oronzo-Barocio et al., 1999). Today *Aloe* is still a popular folk medicine among peoples of Indian, Chinese, and Mexican origin. Recent surveys have indicated that it is one of the three most used

botanicals of middle-aged Mexican women (Zenk et al., 2001); elderly Hispanic and non-Hispanic patients (Zeilmann et al., 2003); asthmatic patients in Trinidad (Clement et al., 2005); low-income, nutritionally vulnerable children in Kansas and Wisconsin (Lohse et al., 2006), Italian women (Zaffani et al., 2006); and households in Texas (Rivera et al., 2002) and Europe (Pahor, 1995).

#### *Gastrointestinal effects*

*A. vera* gel has a prophylactic and curative effect on gastric lesions (Kandil & Gobran, 1982) and irritable bowel disease (Robinson, 1998). The anti-inflammatory action of *A. vera* gel *in vitro* supports the proposal that it may have a therapeutic effect in inflammatory bowel disease (Langmead et al., 2004).

#### *Laxative effects*

The anthraquinones, which are poorly absorbed from the GIT, are cleaved by gut bacteria to produce aloe-emodin, which is more readily absorbed and responsible for the purgative properties of these preparations (Blumenthal et al., 1998). The laxative effect is believed to take place through water accumulation in the intestine via active Na<sup>+</sup> transport (Ishii et al., 1990) or by water secretion due to a prostaglandin-dependent mechanism (Capasso et al., 1983). The mechanism of the cathartic effect has been studied in a series of papers by Iishii et al. (1981, 1988, 1990, 1994).

#### *Skin and wound healing*

Several studies have shown that *A. vera* gel components can prevent UV or  $\gamma$ -radiation-induced skin reactions in mice and humans, by preventing either the suppression of contact hypersensitivity or the immune suppression induced by the radiation (Williams et al., 1996; Roberts & Travis, 1995; Lee et al., 1997). Wound-healing activity has been partially attributed to the presence of mannose-6-phosphate (Davis et al., 1994). However, the polysaccharides in *A. vera* act as immunostimulants, enhancing the release of cytokines, which, in turn, stimulate an increase in the replication of the fibroblasts that are partially responsible for wound healing (Yates et al., 1992). In an *in vitro* wound-migration assay, purified  $\beta$ -sitosterol from *A. vera* stimulated neovascularization in the mouse Matrigel plug assay and motility of human umbilical vein endothelial cells (Moon et al., 1999).

*Aloe* also encourages wound contraction caused by increased collagen activity (Hegggers et al., 1996). A glycoprotein fraction from *A. vera* was found to accelerate wound healing in a monolayer of human keratinocytes and increase expression of proliferation markers at the immunohistochemical level (Choi et al., 2001). *A. vera* inhibits inflammation in a dose-response manner and

improves wound healing in diabetic mice (Davis & Maro, 1989; Chithra et al., 1998).

#### *Diabetes*

Extracts of *Aloe* gum increases glucose tolerance in both normal and diabetic rats (Al-Awadi & Gumaa, 1987), and *A. vera* sap taken for 4–14 weeks has shown a significant hypoglycaemic effect both clinically and experimentally (Ghannam et al., 1986). *A. vera* leaf pulp and gel extracts were ineffective in lowering the blood sugar level of nondiabetic rats, but the leaf pulp extract showed hypoglycaemic activity in type I and II diabetic rats (Okyar et al., 2001). A significant decrease in blood glucose levels after oral administration of the ethanol extract of *A. vera* gel in streptozotocin-induced diabetic rats was ascribed to the antioxidant effect of the extract (Rajasekaran et al., 2005).

#### *Anti-inflammatory effects*

The anti-inflammatory activity of *A. vera* gel may be due to inhibition of the arachidonic acid pathway through cyclo-oxygenase (Vazquez et al., 1996). Penneys (1981) found that *A. vera* gel and extract inhibited oxidation of arachidonic acid *in vitro*. In *A. vera*-treated burn wounds, PGF<sub>2x</sub> levels decreased while PGE<sub>2</sub> levels increased compared to controls (Hegggers et al., 1979). An aqueous extract from *Aloe* gel inhibited the production of prostaglandin E<sub>2</sub> from arachidonic acid *in vitro* (Vazquez et al., 1996). Yagi et al. (2003) isolated a radical scavenging glycoprotein from *A. vera* gel that inhibits cyclooxygenase-2 and thromboxane A<sub>2</sub> synthase. The aloesin derivatives of *A. vera* possess strong DPPH radical and superoxide anion scavenging activities (Yagi et al., 2002).

#### *Antineoplastic activity*

*In vitro*, aloe-emodin inhibits the growth of Merkel carcinoma cells (Wasserman et al., 2002; Fenig et al., 2004), liver cancer cell lines (Hep G2 and Hep 3B; Kuo et al., 2002), and human promyelocytic leukaemia HL-60 cells (Chen et al., 2004); has antineuroectodermal tumor activity (Pecere et al., 2000); and induces apoptosis in lung carcinoma cell lines (Lee, 2001). Lectin-like substances from the leaves of *A. vera* have been shown to promote the growth of normal human cells in culture but inhibit tumor cell growth (Winters et al., 1981). However, in contrast, aloesin has been shown to stimulate the proliferation of cultured hepatoma SK-Hep 1 cells (Yagi & Takeo, 2003).

The anticancer activity of aloe-emodin is based on its promoting cell death by a neuroectodermal tumor-specific drug uptake (Pecere et al., 2003). Aloe-emodin displays a reduced growth inhibitory and pro-apoptotic

activity in p53 mutant cells with respect to the p53 wild-type line. After aloe-emodin treatment, p53 translocates to the mitochondria inter-membrane space in both neuroblastoma cell lines. Due to its high accumulation in neuroectodermal tumor cells, aloe-emodin could kill tumor cells harboring p53 mutant genes. This property would further contribute to aloe-emodin's specific antitumor activity (Pecere et al., 2003).

Mijatovic et al. (2004) investigated aloe-emodin's ability to modulate survival of mouse L929 fibrosarcoma and rat C6 astrocytoma cells through interference with the activation of inducible nitric oxide synthase and subsequent production of tumoricidal free radical nitric oxide. Aloe-emodin rescued interferon- $\gamma$  interleukin-1-stimulated L929 cells from nitric oxide-dependent killing by reducing their autotoxic nitric oxide release. Aloe-emodin inhibition of tumor cell nitric oxide release coincided with a reduction in cytokine-induced accumulation of transcription and translation products of genes encoding inducible nitric oxide synthase and its transcription factor IRF-1. Aloe-emodin has the capacity to directly kill tumor cells but also to protect them from nitric oxide-mediated toxicity. *In vivo*, *Aloe* polysaccharides have antitumor effects in both Sarcoma 180- and Hepatoma 22-bearing mice, the effect possibly being derived from inducing IL-2 and TNF production and thus improving the immune response (Wang et al., 2001).

#### Other medicinal applications

##### Immunostimulation

Aloeride from *A. vera* has been shown to activate macrophages (Pugh et al., 2001), whereas the polysaccharides have been noted to display adjuvant activity on specific antibody production (t'Hart et al., 1989) and enhance the release of cytokines (Peng et al., 1991). Oronzo-Barocio et al. (1999) observed that immunosuppressed mice treated with *Aloe* gel showed restoration of cellular immune response. Aloesin appears to prevent UV-B-induced immune suppression (Yagi & Takeo, 2003).

##### Protection of the liver and kidney

##### Liver

Intraperitoneal injections of aloe-emodin protected the livers of rats treated with CCl<sub>4</sub>, as shown by a reduction in the elevation of ALT and AST (Arosio et al., 2000). *A. vera* gel decreased the damage to the liver in neonatal streptozotocin-induced type II diabetic rats (Can et al., 2004). *Aloe* injections lowered the ALT by 87% in 38 HbsAg-positive patients with chronic hepatitis (Fan et al., 1989).

Woo et al. (2002) determined that aloe-emodin is a potent inhibitor of hepatic stellate cell activation and proliferation, although the mechanism has not been

elucidated. *Aloe* extract has a cytoprotective effect against 1,4-naphthoquinone-induced hepatotoxicity in primary cultured rat hepatocytes (Norikura et al., 2002).

##### Kidney

In rat kidneys with mild damage caused by type II diabetes, *A. vera* gel extract led to improvement in both histological and biochemical parameters, suggesting a protective effect (Bolkent et al., 2004).

##### Hematological

Two lectin glycoproteins, Aloctin I and Aloctin II, isolated from the leaf pulp showed hemagglutinating activity against rabbit erythrocytes *in vitro* (Winters et al., 1981; Akev & Can, 1999). However, *Aloe* whole-leaf powder fed to rats for 90 days showed no adverse effects on hematological parameters (Zhou et al., 2003). The carbohydrate fraction of *A. vera* has been shown to have hematopoietic activity (Talmadge et al., 2004).

##### Hormonal

Aloe-emodin is a potent hypotensive agent leading to a 79% fall in arterial blood pressure at a dose of 3 mg/kg (Saleem et al., 2001).

*A. vera* leaf extracts (125 mg/kg) reduced the serum levels of both T3 and T4 in male mice, suggesting a possible use in the regulation of hyperthyroidism (Kar et al., 2002).

Antraquinones have been traditionally used for the prevention and palliation of menoxenia and postmenopausal disease and, in an *in vitro* study, Matsuda et al. (2001) found that *A. ferox* extracts enhanced proliferation of MCF-7 cells, indicating that they do, indeed, have estrogenic activity.

##### Neural

Diabetes mellitus has been reported to impair memory function in experimental animals. Since the mammalian hippocampus and cerebral cortex play a pivotal role in memory, Parihar et al. (2004) examined the vulnerability of these regions of the brain to oxidative damage in streptozotocin-diabetic mice. When supplemented with *A. vera* extracts, the oxidative damage in both brain regions was reduced, as shown by a significant decline in both lipid peroxidation and protein carbonyl. Memory impairment and motor dysfunction were also improved.

##### Eyes

Biopharmaceutical studies by Kodym and Bujak (2002) concluded that the addition of *Aloe* extract to eye drops containing neomycin sulphate increased the permeation

of the drug through the cornea, suggesting that it may have a role to play in the treatment of inflammations and infections of the eye.

### Cosmetics

In cosmetics, *Aloe* gel is added to cleansers, moisturizers, shampoos, suntan lotions, and sunburn screens. Aloesin modulates melanogenesis via competitive inhibition of tyrosinase, thus holding promise as a pigmentation-altering agent for cosmetic and therapeutic applications (Jones et al., 2002; Yagi & Takeo, 2003). When considering the physicochemical and microbiological stability of *Aloe* components, Kodym and Bujak (2002) determined that the most advisable base for such ointments is white vaseline, liquid paraffin, solid paraffin, or cholesterol.

### Food supplements

*Aloe* is a popular supplement in health foods, sold for the treatment of obesity, hyperlipidaemia, and acne (Wang et al., 2002). The internal use of the gel is regulated as a dietary supplement in the USA (Code of Federal Regulations, 1991) and Europe (Council of Europe, 1981). Use of the juice and integument of leaves of *A. vera* and *A. ferox* as food, however, is not permitted in Japan (Shioda et al., 2003). An edible coating based on *A. vera* gel has been shown to increase the cold storage and subsequent shelf life of grapes and, in addition, reduces the microbial counts of the stored product (Valverde et al., 2005).

### Pharmacological Activity

The pharmacological difference between the gel and the latex is that the gel does not contain anthraquinone compounds and does not therefore exert laxative action (Newall et al., 1996). Aloemannan is catabolized by human intestinal mucosa or by intestinal microflora to two metabolites, which accumulate mainly in the kidneys (Yagi et al., 2001). Aqueous extracts of *Aloe* enhance the oxidation rate of ethanol rate *in vivo* (Chung et al., 1996).

Aloin can be hydrolyzed in the gut to form aloemodin anthrone, which autooxidizes to a quinone, aloemodin. Barbaloin in *Aloe* drinks is converted to aloindimers and trimers during storage (Shindo et al., 2002).

### Adverse effects/toxicity

Hypersensitivity (Morrow et al., 1980) and allergic conditions to *Aloe* preparations have been reported (Ernst, 2000).

Exposure of rats to emodin resulted in an increased incidence of renal tubule pigmentation and nephropathy

in mice (National Toxicology Program, 2001). In rats that were fed *Aloe* whole leaf powder for 90 days, the kidney weight was significantly increased and, in males, testis weights were significantly increased. Additionally, the pigmentation in renal tubular, mesenteric lymph nodes, and lamina propria of the colonic mucosa were also significantly increased compared to the controls, and proliferation of mesenteric lymph nodes was observed (Zhou et al., 2003).

In humans, there are no published controlled toxicology studies *in vivo*, although several single-case reports are available. One patient experienced massive intraoperative bleeding after consumption of *A. vera* tablets. The cause seems to have been a possible herb-drug interaction between *A. vera* and sevoflurane (Lee et al., 2004). Luyckx (2002) reported a patient with acute renal failure following *Aloe* ingestion where no other cause could be found. A case of severe vomiting after *Aloe* ingestion was reported by Wang et al. (2003), and Willems et al. (2003) published a case of melanosis coli that developed after prolonged anthranoid self-medication. Acute hepatitis has been observed following *A. vera* ingestion (Rabe et al., 2005) and Henoch-Schonlein purpura after an *A. vera* herbal remedy juice was taken for back pain (Evangelos et al., 2005).

Deaths have been reported following the use of *Aloe* as abortifacients. However, there is no evidence that the deaths were due to *Aloe* toxicity (Vago, 1969). Adverse effects of *Aloe* whole-leaf powder have been reported at concentrations of 2 g/kg BW, and the LOAEL for aloin is estimated at 11.8 g/kg BW (Zhou et al., 2003). Pregnant women are advised not to take *Aloe* latex because of its cathartic action, which may cause severe uterine contractions and increase the risk of miscarriage. It should also not be ingested by nursing mothers because of the possibility of causing severe cramps and diarrhea in the infant (Brinker, 1998).

### Conclusion

*Aloe* has been traditionally used worldwide as a folk remedy for various diseases because of its multiple biological activities. The number of preparations containing *Aloe* extracts is vast and consists of pills, capsules, creams, powders, and aqueous solutions. In South Africa, the preparations are often crude, consisting of the plant itself or aqueous infusions, but in the commercial products now available worldwide, the preparations often contain stabilizers and preservatives, since some components are subject to oxidation. The heterogeneous nature of *A. vera* products may contribute to the diverse biologic and therapeutic activities that have been observed. The variations in the composition of *A. vera* often results in products with different chemical and physical properties, making the comparison of products virtually impossible.

The FDA has approved the internal use of the gel only as a dietary supplement and its external use only as a cosmetic ingredient. In general, caution is warranted for internal, long-term use (Shah et al., 1989), although Ikeno et al. (2002) have stated that lifelong *A. vera* ingestion does not cause any obvious harmful and deleterious side effects and could be beneficial for the prevention of age-related pathology. *In vitro* and *in vivo* tests have demonstrated and confirmed the activity of *A. vera* gel; however, there are a number of discrepancies about its therapeutic properties, and clinical studies have not always found it to be effective. It is of concern, however, that there are reports of adverse effects.

A metaanalysis of 10 studies covering a number of the putative therapeutic effects of *Aloe* preparations prompted Vogler and Ernst (1999) to conclude that: "Even though there are some promising results, the clinical effectiveness of oral or topical *A. vera* is not sufficiently defined at present." It is vital that *Aloe* products be certified as to content and identification of compounds. Only then will this allow for an accurate comparison of products as well as their efficacy in the clinical setting.

## References

- Akev N, Can A (1999): Separation and some properties of *Aloe vera* L. leaf pulp lectins. *Phytother Res* 13: 489–493.
- Al-Awadi FM, Gumaa KA (1987): Studies on the activity of individual plants of an antidiabetic plant mixture. *Acta Diabetol Lat* 24: 37–41.
- Arosio B, Gagliano N, Fusaro LM, Parmeggiani L, Tagliabue J, Galetti P, De Castri D, Moscheni C, Annoni G (2000): Aloe-emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. *Pharmacol Toxicol* 87: 229–233.
- Blumenthal M (1998): *The Complete Commission E Monographs*. Boston, Integrative Medicine Publishers, pp. 80–81.
- Bolkent S, Akev N, Ozsoy N, Sengezer-Inceli M, Can A, Alper O, Yanardag R (2004): Effect of *Aloe vera* (L.) Burm. Fil. leaf gel and pulp extracts on kidney in type-II diabetic rat models. *Indian J Exp Biol* 42: 48–52.
- Brinker F (1998): *Herb Contraindications and Drug Interactions*, 2nd ed. Sandy, OR, Eclectic Medical, pp. 28–30.
- Bruneton J (1995): *Pharmacognosy, Phytochemistry, Medicinal Plants*. Hampshire, England, Intercept, pp. 434–436.
- Can A, Akev N, Ozsoy N, Bolkent S, Arda BP, Yanardag R, Okyar A (2004): Effect of *Aloe vera* leaf gel and pulp extracts on the liver in type-II diabetic rat models. *Biol Pharm Bull* 27: 694–698.
- Cao H, Liu Y (2003): Determination of aloin in *Aloes* by HPLC. *Zhongguo Zhong Yao Za Zhi* 28: 349–351.
- Capasso F, Mascolo N, Autore G, De Simone F, Senatore F (1983): Effect of indomethacin on aloin and 1,8 dioxanthraquinone-induced production of prostaglandins in rat isolated colon. *Prostaglandins* 26: 557–562.
- Castleman M (1991): *The Healing Herbs. The Ultimate Guide to the Curative Power of Nature's Medicines*. Emmanus, PA, Rodale Press, pp. 42–44.
- Chen JD, Li W, Li SY (2002): Quantitative determination of barbaloin in *Aloe* capsule by high performance liquid chromatography. *Se Pu* 20: 367–368.
- Chen HC, Hsieh WT, Chang WC, Chung JG (2004): Aloe-emodin induced *in vitro* G2/M arrest of cell cycle in human promyelocytic leukemia HL-60 cells. *Food Chem Toxicol* 42: 1251–1257.
- Chithra P, Sajithlal GB, Chandrakasan G (1998): Influence of *Aloe vera* on the healing of dermal wounds in diabetic rats. *J Ethnopharmacol* 59: 195–201.
- Choi SW, Son BW, Son YS, Park YI, Lee SK, Chung MH (2001): The wound-healing effect of a glycoprotein fraction isolated from *Aloe vera*. *Br J Dermatol* 145: 535–545.
- Chung JH, Cheong JC, Lee JY, Roh HK, Cha YN (1996): Acceleration of the alcohol oxidation rate in rats with aloin, quinine derivative of *Aloe*. *Biochem Pharmacol* 52: 1461–1468.
- Clement YN, Williams AF, Aranda D, Chase R, Watson N, Mohammed R, Stubbs O, Williamson D (2005): Medicinal herb use among asthmatic patients attending a speciality care facility in Trinidad. *BMC Complement Altern Med* 5: 3.
- Code of Federal Regulations (1991): *Title 21 (Food and Drugs)*, part 170–199. Washington, DC, US Government Printing Office.
- Council of Europe (1981): *Flavoring Substances and Natural Source of Flavorings*. 3rd ed. Moulins-les Metz, France, Maisonneuve, pp. 376.
- Davis RH, Donato JJ, Hartman GM, Haas RC (1994): Anti-inflammatory and wound healing activity of growth substance in *Aloe vera*. *J Am Podiatr Med Assoc* 84: 77–81.
- Davis RH, Maro NP (1989): *Aloe vera* and gibberellin. Anti-inflammatory activity in diabetes. *J Am Podiatr Med Assoc* 79: 24–26.
- Davis RH, Donato JJ, Hartman GM, Haas RC (1994): Anti-inflammatory and wound healing activity of a growth substance in *Aloe vera*. *J Am Podiatr Med Assoc* 84: 77–81.
- Duke JA (1997): *The Green Pharmacy*. Emmaus, PA, Rodale Press, pp. 392–395.
- Eberendu AR, Luta G, Edwards JA, McAnalley BH, Davis B, Rodriguez S, Henry CR (2005): Quantitative colorimetric analysis of aloe polysaccharides as a measure of *Aloe vera* quality in commercial products. *J AOAC Int* 88: 684–691.
- ElSohly MA, Gul W, Murphy TP (2004): Analysis of the anthraquinones aloe-emodin and aloin by gas chromatography/mass spectrometry. *Int Immunopharmacol* 4: 1739–1744.

- Ernst E (2000): Adverse effects of herbal drugs in dermatology. *Br J Dermatol* 143: 923–929.
- Esua MF, Rauwald J-W (2006): Novel bioactive maloyl glucans from *Aloe vera* gel: isolation, structure elucidation and *in vitro* bioassays. *Carbohydr Res* 341: 355–364.
- Evangelos C, Spyros K, Spyros D (2005): Henoch-Schonlein purpura associated with *Aloe vera* administration. *Eur J Int Med* 16: 59–60.
- Fan YJ, Li M, Yang WL, Qin L, Zou J (1989): Protective effect of extracts from *Aloe vera* L. var. *chinensi* (Haw.) Berg. On experimental hepatic lesions and a primary clinical study on the injection of in patients with hepatitis. *Zhongguo Zhong Yao Za Zhi* 14: 746–748.
- Femenia A, Sanchez E, Simal S, Rossello C (1999): Compositional features of polysaccharides from *Aloe vera* L. (*Aloe barbadensis* Miller) plant tissue. *Carbohydr Polym* 39: 109–117.
- Femenia A, Garcia-Pascual P, Simal S, Rossello C (2003): Effects of heat treatment and dehydration on bioactive polysaccharide acemannan and cell wall polymers from *Aloe barbadensis*. *Carbohydr Polym* 51: 397–405.
- Fenig E, Nordenberg J, Beery E, Sulkes J, Wasserman L (2004): Combined effect of aloe-emodin and chemotherapeutic agents on the proliferation of an adherent variant cell line of Merkel cell carcinoma. *Oncol Rep* 11: 213–217.
- Ghannam N, Kingston M, Al-Meshaal IA, Tariq M, Parman NS, Wodhouse N (1986): The antidiabetic activity of aloes: Preliminary clinical and experimental observations. *Horm Res* 24: 288–294.
- Heggors JP, Kucukcelebi A, Listengarten D, Stabenau J, Ko F, Broemeling LD, Robson MC, Winters WD (1996): Beneficial effect of *Aloe* on wound healing in a excisional wound model. *J Alt Complement Med* 2: 271–277.
- Heggors JP, Loy G, Robson MC (1979): Histological demonstration of prostaglandins and thromboxanes in burned tissue. *J Surgical Res* 28: 110–117.
- Hu Y, Xu J, Hu Q (2003): Evaluation of antioxidant potential of *Aloe vera* (*Aloe barbadensis* Miller) extracts. *J Agric Food Chem* 51: 7788–7791.
- Ikeno Y, Hubbard GB, Lee S, Yu BP, Herlihy JT (2002): The influence of long-term *Aloe vera* ingestion on age-related disease in male Fischer 344 rats. *Phytother Res* 16: 712–718.
- Ishii Y, Tanizawa H, Takino Y (1981): Studies of *Aloe*. IV. Mechanism of cathartic effect. (3). *Biol Pharm Bull* 17: 495–497.
- Ishii Y, Tanizawa H, Takino Y (1988): Studies of *Aloe*. II. Mechanism of cathartic effect. *Yakugaku Zasshi* 108: 904–910.
- Ishii Y, Tanizawa H, Takino Y (1990): Studies of *Aloe*. III. Mechanism of cathartic effect. (2). *Chem Pharm Bull* 38: 197–200.
- Ishii Y, Tanizawa H, Takino Y (1994): Studies of *Aloe*. V. Mechanism of cathartic effect. (4). *Biol Pharm Bull* 17: 651–653.
- Jones K, Hughes J, Hong M, Jia Q, Orndorff S (2002): Modulation of melanogenesis by aloesin: A competitive inhibitor of tyrosinase. *Pigment Cell Res* 15: 335–340.
- Kandil A, Gobran W (1982): Protection of gastric mucosa by *Aloe vera*. *Bull Islam Med* 2: 503–511.
- Kar A, Panda S, Bharti S (2002): Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. *J Ethnopharmacol* 81: 281–285.
- Kodym A, Bujak T (2002): Physicochemical and microbiological properties as well as stability of ointments containing *Aloe* extract (*Aloe arborescens* Mill.) or *Aloe* extract associated to neomycin sulphate. *Pharmazie* 57: 834–837.
- Kuzuya H, Tamai I, Beppu H, Shimpō K, Chihara T (2001): Determination of aloenin, barbaloin and isobarbaloin in aloe species by micellar electrokinetic chromatography. *J Chromatogr B Biomed Sci Appl* 752: 91–97.
- Langmead L, Makins RJ, Rampton DS (2004): Anti-inflammatory effects of *Aloe vera* gel in human colorectal mucosa *in vitro*. *Aliment Pharmacol Ther* 19: 521–527.
- Lee CK, Han SS, Mo YK, Kim RS, Chung MH, Park YI, Lee SK, Kim YS (1997): Prevention of ultraviolet radiation-induced suppression of accessory cell function of Langerhans cells by *Aloe vera* gel components. *Immunopharmacology* 37: 153–162.
- Lee KY, Weinstraub ST, Yu BP (2000): Isolation and identification of a phenolic antioxidant from *Aloe barbadensis*. *Free Radic Biol Med* 28: 261–265.
- Lee HZ (2001): Protein kinase C involvement in aloe-emodin- and emodin-induced apoptosis in lung carcinoma cell. *Br J Pharmacol* 134: 1093–1103.
- Lee A, Chui PT, Aun CS, Gin T, La AS (2004): Possible interaction between sevoflurane and *Aloe vera*. *Ann Pharmacother* 38: 1651–1654.
- Lindsey KL, Jäger AK, Viljoen AM (2002): Cyclooxygenase inhibitory activity of *Aloe* species. *S Afr J Bot* 68: 47–50.
- Lohse B, Stotts JL, Priebe JR (2006): Survey of herbal use by Kansas and Wisconsin WIC participants reveals moderate, appropriate use and identifies herbal education needs. *J Am Diet Assoc* 106: 227–237.
- Luyckx VA, Ballantine R, Claeys M, Cuyckens F, Van den Heuvel H, Cimanga RK (2002): Herbal remedy-associated acute renal failure secondary to Cape aloes. *Am J Kidney Dis* 39: E13.
- Mijatovic S, Maksimovic-Ivanic D, Radovic J, Popadic D, Momcilovic M, Harhaji L, Miljkovic D, Trajkovic V (2004): Aloe-emodin prevents cytokine-induced tumor cell death: The inhibition of auto-toxic nitric oxide release as a potential mechanism. *Cell Mol Life Sci* 61: 1805–1815.
- Moon EJ, Lee YM, Lee OH, Lee MJ, Lee SK, Chung MH, Park YI, Sung CK, Choi JS, Kim KW (1999): A novel angiogenic factor derived from *Aloe vera* gel: beta-Sitosterol, a plant sterol. *Angiogenesis* 3: 117–123.

- Morrow DM, Rapaport MJ, Strick RA (1980): Hypersensitivity to *Aloe*. *Arch Dermatol* 116: 1064–1065.
- Nakamura H, Okuyama T (1990): Gas chromatographic and mass spectral determination of aloenin in skin-care cosmetics. *J Chromatogr* 509: 377–382.
- National Toxicology Program (2001): NTP toxicology and carcinogenesis studies of emodin (CAS NO. 518-82-1). Feed studies in F344/N rats and B6C3F1 mice. *Natl Toxicol Program Tech Rep Ser* 493: 1–278.
- Newall CA, Anderson LA, Phillipson JD (1996): *Herbal Medicines: A Guide for Health-Care Professionals*. London, Pharmaceutical Press, pp. 25–27.
- Norikura T, Kennedy DO, Nyarko AK, Kojima A, Matsui-Yuasa I (2002): Protective effect of aloe extract against the cytotoxicity of 1,4-naphthoquinone in isolated rat hepatocytes involves modulations in cellular thiol levels. *Pharmacol Toxicol* 90: 278–284.
- Okyar A, Can A, Akev N, Baktir G, Sutlupinar N (2001): Effect of *Aloe vera* leaves on blood glucose level in type I and type II diabetic rat models. *Phytother Res* 15: 157–161.
- Oronzo-Barocio A, Zaitseva G, Chavez-Anaya A, Arceta-Gonzalez VI, Puebla-Perez AM, Alfaro-Bustamante F, Zimina IV, Arion VY (1999): Modulation of immune response of BALB/Mice bearing lymphoma L5178Y treated with bitter yellow juice of *Aloe vera* (L) *in vivo*. *Russ J Immunol* 4: 43–50.
- Pahor M, Mugelli A, Guralnik JM, Manto A, Carosella L, Sgadari A, Carbonin PU (1995): Age and laxative use in hospitalised patients. A report of the “Gruppo Italiano di Farmacovigilanza nell’Anziano: GIFA.” *Aging* 7: 128–135.
- Parihar MS, Chaudhary M, Shetty R, Hemnani T (2004): Susceptibility of hippocampus and cerebral cortex to oxidative damage in streptozotocin treated mice: Prevention by extracts of *Withania somnifera* and *Aloe vera*. *J Clin Neurosci* 11: 397–402.
- Pecere T, Gazzola MV, Mucignat C, Parolin C, Vecchia FD, Cavaggioni A, Basso G, Diaspro A, Salvato B, Carli M, Palu G (2000): Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. *Cancer Res* 60: 2800–2804.
- Pecere T, Sarinella F, Salata C, Gatto B, Bet A, Dalla Vecchia F, Diaspro A, Carli M, Palumbo M, Palu G (2003): Involvement of p53 in specific anti-neuroectodermal tumor activity of aloe-emodin. *Int J Cancer* 106: 836–847.
- Peng SY, Norman J, Curtin G, Corrier D, McDaniel HR, Busbee D (1991): Decreased mortality in Norman murine sarcoma in mice treated with the immunomodulator, Acemannan. *Mol Biother* 3: 79–87.
- Penneys NS (1981): Inhibition of arachidonic acid oxidation by vehicle components. *Acta Derm Venereol* 62: 59–61.
- Perkins SL, Livesey JF (1993): A rapid high-performance thin-layer chromatographic urine screen for laxative abuse. *Clin Biochem* 26: 179–181.
- Pugh N, Ross SA, ElSohly MA, Pasco DS (2001): Characterization of aloeride, a new high-molecular-weight polysaccharide from *Aloe vera* with potent immunostimulative activity. *J Agric Food Chem* 49: 1030–1034.
- Rabe C, Musch A, Schirmacher P, Kruis W, Hoffmann R (2005): Acute hepatitis induced by an *Aloe vera* preparation: A case report. *World J Gastroenterol* 11: 303–304.
- Rajasekaran S, Sivagnanam K, Ravi K, Subramanian S (2005): Antioxidant effect of *Aloe vera* gel extract in streptozotocin-induced diabetes in rats. *Pharmacol Rep* 57: 90–96.
- Reynolds T, Dweck AC (1999): *Aloe vera* leaf gel: A review update. *J Ethnopharmacol* 68: 3–37.
- Rivera JO, Oritz M, Lawson ME, Verma KM (2002): Evaluation of the use of complementary and alternative medicine in the largest United States-Mexico border city. *Pharmacotherapy* 22: 256–264.
- Roberts DB, Travis EL (1995): Acemannan-containing wound dressing gel reduces radiation-induced skin reactions in C3H mice. *Int J Radiat Oncol Biol Phys* 32: 1047–1052.
- Robinson M (1998): Medical therapy of inflammatory bowel disease for the 21st century. *Eur J Surg Suppl* 582: 90–98.
- Robson MC, Heggors JP, Hagstrom WJ (1982): Myth, magic, witchcraft or fact? *Aloe vera* revisited. *J Burn Care Rehab* 3: 157–162.
- Saccu D, Bongoni P, Procida G (2001): *Aloexudates*: Characterization by reversed phase HPLC and headspace GC-MS. *J Agric Food Chem* 49: 4526–4530.
- Saleem R, Faizi S, Siddiqui BS, Ahmed M, Hussain SA, Qazi A, Dar A, Ahmad SI, Qazi MH, Akhtar S, Hasnain SN (2001): Hypotensive effect of chemical constituents from *Aloe barbadensis*. *Planta Med* 67: 757–760.
- Shah AH, Qureshi S, Tariq M, Ageel AM (1989): Toxicity studies on six plants used in the traditional Arab system of medicine. *Phytother Res* 3: 125–129.
- Shindo T, Ushiyama H, Kan K, Uehara S, Yasuda K, Takano I, Saito K (2002): Contents of barbaloin-related compounds in aloe drinks and their change during storage. *Shokuhin Eiseigaku Zasshi* 43: 122–126.
- Shioda H, Satoh K, Nagai F, Okubo T, Seto T, Hamano T, Kamimura H, Kano I (2003): Identification of *Aloe* species by random amplified polymorphic DNA (RAPD) analysis. *Shokuhin Eiseigaku Zasshi* 44: 203–207.
- Speranza G, Morelli CF, Tubaro A, Altinier G, Duri L, Manitto P (2005): Aloeresin I, an anti-inflammatory 5-methylchromone from Cape *Aloe*. *Planta Med* 71: 79–81.
- Swanson LN (1995): Therapeutic value of *Aloe vera*. *US Pharm* 20: 26–35.
- Talmadge J, Chavez J, Jacobs L, Munger C, Chinnah T, Chow JT, Williamson D, Yates K (2004): Fractionation of *Aloe vera* L. inner gel, purification and molecular profiling of activity. *Int Immunopharmacol* 4: 1757–1773.

- T'Hart LA, van den Berg AJ, Kuis L, van Dijk H, Labadie RP (1989): An anti-complementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of *Aloe vera*. *Planta Med* 55: 509–512.
- Turner CE, Williamson DA, Stroud PA, Talley DJ (2004): Evaluation and comparison of commercially available *Aloe vera* L. products using size exclusion chromatography with refractive index and multi-angle laser light scattering detection. *Int Immunopharmacol* 4: 1727–1737.
- Tyler VE, Brady LY, Robbers JE (1981): *Pharmacognosy*, 8th ed. Philadelphia, Lea and Febiger, pp. 61–63.
- Vago O (1969): Toxic and caustic complications through use of so-called abortifacients. *Z Geburtshilfe Perinatol* 170: 272–277.
- Valverde JM, Valero D, Martinez-Romera D, Guillen F, Castillo S, Serrano M (2005): Novel edible coating based on *Aloe vera* gel to maintain table grape quality and safety. *J Agric Food Chem* 53: 7807–7813.
- Van Wyk B-E, Van Oudtshoorn B, Gericke N (1997): *Medicinal plants of South Africa*. Pretoria, Briza Publications, pp. 40.
- Vazquez B, Avila G, Segura D, Escalante B (1996): Anti-inflammatory activity of extracts from *Aloe vera* gel. *J Ethnopharmacol* 55: 69–75.
- Vogler BK, Ernst E (1999): *Aloe vera*: A systematic review of its clinical effectiveness. *Br J Gen Pract* 349: 823–828.
- Wang W, Cuyckens F, Van den Heuvel H, Apers S, Pieters L, Steenkamp V, Stewart MJ, Luyckx VA, Claeys M (2003): Structural characterization of chromone C-glucosides in a toxic herbal remedy. *Rapid Commun Mass Spectrom* 17: 49–55.
- Wang Z, Wang Y, Huang Z, Zhong S, Wu Y, Yu L (2001): Study on antitumor effects and mechanism of aloe polysaccharides. *Zhong Yao Cai* 24: 350–353.
- Wang DX, Yang GL, Wang LY, Song XR (2000): Determination of the active components in Chinese herb *Aloe vera* L. var. *chinensis* (Haw.) Berger by capillary zone electrophoresis. *Se Pu* 18: 423–425.
- Wang A, Zhou Y, Wu F, He P, Fang Y (2004): Determination of active ingredients in Huangdan Yinchen Keli by CZE with amperometric detection. *J Pharm Biomed Anal* 35: 959–964.
- Wang ZW, Wang Y, Huang ZS (2002): The radio-protective effect of *Aloe* polysaccharides on irradiated mice. *Chin Trad Herb Drugs* 33: 251–254.
- Wasserman L, Avigad S, Beery E, Nordenberg J, Fenig E (2002): The effect of aloe emodin on the proliferation of a new Merkel carcinoma cell line. *Am J Dermatopathol* 24: 17–22.
- Wichtl M, Bisset NG (1994): *Herbal Drugs and Phytopharmaceuticals*. Stuttgart, Medipharma Scientific Publishers, pp. 463–469.
- Williams MS, Burk M, Loprinze CL, Hill M, Schomberg PJ, Nearhood K, O'Fallon JR, Laurie JA, Shanahan TG, Moore RL, Urias RE, Kuske RR, Engel RE, Eggleston WD (1996): Phase II double-blind evaluation of an *Aloe vera* gel as a prophylactic agent for radiation-induced skin toxicity. *Int J Radiat Oncol Biol Phys* 36: 345–349.
- Willems M, van Buuren HR, de Krijger R (2003): Anthranoid self-medication causing rapid development of melanosis coli. *Neth J Med* 61: 22–24.
- Winters D, Benavides R, Clouse WJ (1981): Effects of *Aloe* extracts on human normal and tumor cells *in vitro*. *Eco Bot* 35: 89–95.
- Woo SW, Nan JX, Lee SH, Park EJ, Zhao YZ, Sohn DH (2002): Aloe-emodin suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. *Pharmacol Toxicol* 90: 193–198.
- Yagi A, Hamano S, Tanaka T, Kaneo Y, Fujioka T, Mihashi K (2001): Biodisposition of FITC-labeled aloe-mannan in mice. *Planta Med* 67: 297–300.
- Yagi A, Kabash A, Mizuno K, Moustafa SM, Khalifa TI, Tsuji H (2003): Radical scavenging glycoprotein inhibiting cyclooxygenase-2 and thromboxane A<sub>2</sub> synthase from *Aloe vera* gel. *Planta Med* 69: 269–271.
- Yagi A, Kabash A, Okamura N, Haraguchi H, Moustafa SM, Khalifa TI (2002): Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin derivatives in *Aloe vera*. *Planta Med* 68: 957–960.
- Yagi A, Takeo S (2003): Anti-inflammatory constituents, aloesin and aloemannan in *Aloe* species and effects of tanshinon VI in *Salvia miltiorrhiza* on heart. *Yakugaku Zasshi* 123: 517–532.
- Yamamoto M, Ishikawa M, Masui T, Nakazawa H, Kabasawa Y (1985): Liquid chromatographic determination of barbaloin (aloin) foods. *J Assoc Off Anal Chem* 68: 493–494.
- Yates KM, Rosenberg LJ, Harris CK, Bronstad DC, King GK, Bichle GA, Walker B, Ford CR, Hall JE, Tizard IR (1992): Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. *Vet Immunol Immunopathol* 35: 177–189.
- Yuan AX (1993): The molecular structure of iso-aloesin isolated from the leaves of *Aloe vera* L. var. *chinensis* (Haw.) Berger. *Zhongguo Zhong Yao Za Zhi* 18: 609–611.
- Yuan A, Kang S, Qin L, Ruan B, Fan Y (1991): Isolation and identification of aloesin from the leaves of *Aloe vera* L. var. *chinensis* (Haw.) Berger. *Zhongguo Zhong Yao Za Zhi* 16: 292–293.
- Zaffani S, Cuzzolin L, Benoni G (2006): Herbal products: Behaviors and beliefs among Italian women. *Pharmacoepidemiol Drug Saf* 15: 354–359.
- Zaffaroni M, Mucignat C, Pecere T, Zagotto G, Frapolli R, D'Incalci M, Zucchetti M (2003): High-performance liquid chromatographic assay for the determination of aloe-emodin in mouse plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 796: 113–119.
- Zeilmann CA, Dole EJ, Skipper BJ, McCabe M, Dog TL, Rhyne RL (2003): Use of herbal medicine by elderly Hispanic and non-Hispanic white patients. *Pharmacotherapy* 23: 526–532.

- Zenk SN, Shaver JL, Peragallo N, Fox P, Chavez N (2001): Use of herbal therapies among midlife Mexican women. *Health Care Women Int* 22: 585–597.
- Zhang X-f, Wang, H-m, Song Y-l, Nie L-h, Wang L-f, Liu B, Shen P-p, Liu Y (2006): Isolation, structure elucidation, antioxidative and immunomodulatory properties of two novel dihydrocoumarins from *Aloe vera*. *Bioorg Med Chem Lett* 16: 949–953.
- Zheng W, Wang S, Chen X, Hu Z (2004): Identification and determination of active anthraquinones in Chinese teas by micellar electrokinetic capillary chromatography. *Biomed Chromatogr* 18: 167–172.
- Zhou Y, Feng Y, Wang H, Yang H (2003): 90-day subchronic toxicity study of *Aloe* whole-leaf powder. *Wei Sheng Yan Jiu* 32: 590–593.

Copyright of *Pharmaceutical Biology* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.